134 related articles for article (PubMed ID: 2220756)
41. Identification and characterization of an essential, activating regulatory element of the human SIS/PDGFB promoter in human megakaryocytes.
Jin HM; Brady ML; Fahl WE
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7563-7. PubMed ID: 8356057
[TBL] [Abstract][Full Text] [Related]
42. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
43. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system.
Chaudhry A; Papanicolaou V; Oberg K; Heldin CH; Funa K
Cancer Res; 1992 Feb; 52(4):1006-12. PubMed ID: 1310635
[TBL] [Abstract][Full Text] [Related]
44. Induction of acidic fibroblast growth factor and full-length platelet-derived growth factor expression in human cardiac allografts. Analysis by PCR, in situ hybridization, and immunohistochemistry.
Zhao XM; Yeoh TK; Frist WH; Porterfield DL; Miller GG
Circulation; 1994 Aug; 90(2):677-85. PubMed ID: 7519129
[TBL] [Abstract][Full Text] [Related]
45. Histologic criteria for classification and differential diagnosis of chronic myeloproliferative disorders.
Frisch B; Bartl R; Burkhardt R; Jäger K
Haematologia (Budap); 1984; 17(2):209-26. PubMed ID: 6534829
[TBL] [Abstract][Full Text] [Related]
46. [Histopathologic diagnosis of bone marrow in leukemia and related disorders].
Kikuchi M; Ohshima K; Kobari S
Rinsho Byori; 1991 Dec; 39(12):1245-9. PubMed ID: 1779461
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal gammopathy in chronic myeloproliferative disorders.
Economopoulos T; Economidou J; Papageorgiou E; Dervenoulas J; Christodoulides C; Pappa V; Karakassis D; Terzoglou C; Athanassiadou S; Chalevelakis G
Blut; 1989 Jan; 58(1):7-9. PubMed ID: 2917205
[TBL] [Abstract][Full Text] [Related]
48. Bone marrow stromal cells in myeloproliferative disorders.
Hirata J; Takahira H; Kaneko S; Nishimura J; Nawata H
Acta Haematol; 1989; 82(1):35-9. PubMed ID: 2505472
[TBL] [Abstract][Full Text] [Related]
49. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
Thiele J; Funke S; Holgado S; Choritz H; Georgii A
Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
[TBL] [Abstract][Full Text] [Related]
50. Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis.
Kimura A; Nakata Y; Hyodo H; Kuramoto A; Satow Y
Br J Haematol; 1994 Feb; 86(2):303-7. PubMed ID: 8199019
[TBL] [Abstract][Full Text] [Related]
51. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
52. Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.
Guo BB; Linden MD; Fuller KA; Phillips M; Mirzai B; Wilson L; Chuah H; Liang J; Howman R; Grove CS; Malherbe JA; Leahy MF; Allcock RJ; Erber WN
Br J Haematol; 2020 Jan; 188(2):272-282. PubMed ID: 31426129
[TBL] [Abstract][Full Text] [Related]
53. [Role of PDGF/PDGFR Pathway in Essential Thrombocythemia and Its Action Mechanism].
Zhou LX; Liang EY; Ye JY; Yang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):526-30. PubMed ID: 27151023
[TBL] [Abstract][Full Text] [Related]
54. Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor-alpha, -beta in human diabetic nephropathy.
Uehara G; Suzuki D; Toyoda M; Umezono T; Sakai H
Clin Exp Nephrol; 2004 Mar; 8(1):36-42. PubMed ID: 15067514
[TBL] [Abstract][Full Text] [Related]
55. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
56. Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease.
Bernabei PA; Arcangeli A; Casini M; Grossi A; Padovani R; Rossi Ferrini P
Br J Haematol; 1986 Jun; 63(2):353-7. PubMed ID: 3755056
[TBL] [Abstract][Full Text] [Related]
57. A reversible defect of platelet PDGF content in myeloproliferative disorders.
Baglin TP; Price SM; Boughton BJ
Br J Haematol; 1988 Aug; 69(4):483-6. PubMed ID: 3408684
[TBL] [Abstract][Full Text] [Related]
58. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
59. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
60. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).
Wróbel T; Mazur G; Surowiak P; Wolowiec D; Jelen M; Kuliczkowsky K
Pathol Oncol Res; 2003; 9(3):170-3. PubMed ID: 14530810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
